Cargando…
MON-443 Periostin Concentrations in Childhood-Onset Craniopharyngioma Patients
Objective: The extracellular matrix protein periostin is highly expressed in adamantinomatous craniopharyngioma-associated fibroblasts. Periostin has been further identified as a novel marker for Non-Alcoholic Fatty Liver Disease (NAFLD). Half of childhood-onset craniopharyngioma patients (CP) with...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550905/ http://dx.doi.org/10.1210/js.2019-MON-443 |
_version_ | 1783424290167717888 |
---|---|
author | Heinks, Kerstin De Schutter-Nüsse, Caroline Boekhoff, S Bogusz, Agnieszka Zhu, Jinzhou Peng, Jungxiang Muller, Hermann |
author_facet | Heinks, Kerstin De Schutter-Nüsse, Caroline Boekhoff, S Bogusz, Agnieszka Zhu, Jinzhou Peng, Jungxiang Muller, Hermann |
author_sort | Heinks, Kerstin |
collection | PubMed |
description | Objective: The extracellular matrix protein periostin is highly expressed in adamantinomatous craniopharyngioma-associated fibroblasts. Periostin has been further identified as a novel marker for Non-Alcoholic Fatty Liver Disease (NAFLD). Half of childhood-onset craniopharyngioma patients (CP) with hypothalamic syndrome develop NAFLD. We hypothesized that periostin concentration is elevated in biological fluids of CP and associated with pathological hepatic parameters, indicating increased risk for NAFLD. Design: Cross-sectional study on patients with sellar masses (SMP) recruited in the German Craniopharyngioma Registry. Patients: 35 SMP (32 CP, 2 xanthogranuloma, one pilocytic astrocytoma), 3 short-statured patients with isolated growth hormone deficiency (GHD), 5 short-statured patients with normal findings in GH stimulating tests and decreased insulin-like growth factor (IGF)-1 (IGF-1D) and 7 healthy controls. Measurements: Periostin concentrations were measured by Elisa in serum (32 CP, 2 xanthograuloma, 3 GHD, 5 IGF-1D and 7 healthy controls), urine (27 CP, 3 GHD, 5 IGF-1D, 7 healthy controls) and saliva (18 CP, 3 GHD, 3 IGF-1D, 7 healthy controls). Results: Periostin serum, urine and saliva concentrations in CP were similar to concentrations of the other groups. Hypothalamic involvement/hypothalamic lesions, degree of obesity (BMI SDS) as well as hepatic enzymes were not associated with elevated periostin concentrations. Due to low patient numbers with pathological hepatic parameters, missing imaging data on the degree of steatosis hepatis and the lack of histological proof of NAFLD no definitive conclusions can be drawn from measured periostin concentrations in serum. Interestingly, the subgroup of patients with decreased IGF-1 levels showed elevated concentrations of serum periostin when compared with other groups. Conclusions: Periostin concentrations in biological fluids of CP are not associated with known risk factors for NAFLD such as hepatic and metabolic parameters, obesity and hypothalamic lesions. Accordingly, periostin does not seem to be a suitable marker for NAFLD in childhood-onset CP. The association between decreased IGF-1 and increased periostin concentrations should be part of further investigation. |
format | Online Article Text |
id | pubmed-6550905 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Endocrine Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-65509052019-06-13 MON-443 Periostin Concentrations in Childhood-Onset Craniopharyngioma Patients Heinks, Kerstin De Schutter-Nüsse, Caroline Boekhoff, S Bogusz, Agnieszka Zhu, Jinzhou Peng, Jungxiang Muller, Hermann J Endocr Soc Neuroendocrinology and Pituitary Objective: The extracellular matrix protein periostin is highly expressed in adamantinomatous craniopharyngioma-associated fibroblasts. Periostin has been further identified as a novel marker for Non-Alcoholic Fatty Liver Disease (NAFLD). Half of childhood-onset craniopharyngioma patients (CP) with hypothalamic syndrome develop NAFLD. We hypothesized that periostin concentration is elevated in biological fluids of CP and associated with pathological hepatic parameters, indicating increased risk for NAFLD. Design: Cross-sectional study on patients with sellar masses (SMP) recruited in the German Craniopharyngioma Registry. Patients: 35 SMP (32 CP, 2 xanthogranuloma, one pilocytic astrocytoma), 3 short-statured patients with isolated growth hormone deficiency (GHD), 5 short-statured patients with normal findings in GH stimulating tests and decreased insulin-like growth factor (IGF)-1 (IGF-1D) and 7 healthy controls. Measurements: Periostin concentrations were measured by Elisa in serum (32 CP, 2 xanthograuloma, 3 GHD, 5 IGF-1D and 7 healthy controls), urine (27 CP, 3 GHD, 5 IGF-1D, 7 healthy controls) and saliva (18 CP, 3 GHD, 3 IGF-1D, 7 healthy controls). Results: Periostin serum, urine and saliva concentrations in CP were similar to concentrations of the other groups. Hypothalamic involvement/hypothalamic lesions, degree of obesity (BMI SDS) as well as hepatic enzymes were not associated with elevated periostin concentrations. Due to low patient numbers with pathological hepatic parameters, missing imaging data on the degree of steatosis hepatis and the lack of histological proof of NAFLD no definitive conclusions can be drawn from measured periostin concentrations in serum. Interestingly, the subgroup of patients with decreased IGF-1 levels showed elevated concentrations of serum periostin when compared with other groups. Conclusions: Periostin concentrations in biological fluids of CP are not associated with known risk factors for NAFLD such as hepatic and metabolic parameters, obesity and hypothalamic lesions. Accordingly, periostin does not seem to be a suitable marker for NAFLD in childhood-onset CP. The association between decreased IGF-1 and increased periostin concentrations should be part of further investigation. Endocrine Society 2019-04-30 /pmc/articles/PMC6550905/ http://dx.doi.org/10.1210/js.2019-MON-443 Text en Copyright © 2019 Endocrine Society https://creativecommons.org/licenses/by-nc-nd/4.0/ This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Neuroendocrinology and Pituitary Heinks, Kerstin De Schutter-Nüsse, Caroline Boekhoff, S Bogusz, Agnieszka Zhu, Jinzhou Peng, Jungxiang Muller, Hermann MON-443 Periostin Concentrations in Childhood-Onset Craniopharyngioma Patients |
title | MON-443 Periostin Concentrations in Childhood-Onset Craniopharyngioma Patients |
title_full | MON-443 Periostin Concentrations in Childhood-Onset Craniopharyngioma Patients |
title_fullStr | MON-443 Periostin Concentrations in Childhood-Onset Craniopharyngioma Patients |
title_full_unstemmed | MON-443 Periostin Concentrations in Childhood-Onset Craniopharyngioma Patients |
title_short | MON-443 Periostin Concentrations in Childhood-Onset Craniopharyngioma Patients |
title_sort | mon-443 periostin concentrations in childhood-onset craniopharyngioma patients |
topic | Neuroendocrinology and Pituitary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550905/ http://dx.doi.org/10.1210/js.2019-MON-443 |
work_keys_str_mv | AT heinkskerstin mon443periostinconcentrationsinchildhoodonsetcraniopharyngiomapatients AT deschutternussecaroline mon443periostinconcentrationsinchildhoodonsetcraniopharyngiomapatients AT boekhoffs mon443periostinconcentrationsinchildhoodonsetcraniopharyngiomapatients AT boguszagnieszka mon443periostinconcentrationsinchildhoodonsetcraniopharyngiomapatients AT zhujinzhou mon443periostinconcentrationsinchildhoodonsetcraniopharyngiomapatients AT pengjungxiang mon443periostinconcentrationsinchildhoodonsetcraniopharyngiomapatients AT mullerhermann mon443periostinconcentrationsinchildhoodonsetcraniopharyngiomapatients |